Entering text into the input field will update the search result below

Acorda inks license deal with Asieris for pre-clinical drug

Aug. 29, 2022 7:20 AM ETAcorda Therapeutics, Inc. (ACOR) StockBy: Dulan Lokuwithana, SA News Editor

Gratitude Concept With Heart Symbol

Eoneren/E+ via Getty Images

  • Commercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat.
  • Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug

Recommended For You

More Trending News

About ACOR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACOR--
Acorda Therapeutics, Inc.